Cover Image
市場調查報告書

全球DNA疫苗市場預測

Global DNA Vaccine Market Outlook 2022

出版商 RNCOS E-Services Pvt. Ltd. 商品編碼 352583
出版日期 內容資訊 英文 85 Pages
訂單完成後即時交付
價格
Back to Top
全球DNA疫苗市場預測 Global DNA Vaccine Market Outlook 2022
出版日期: 2016年08月01日 內容資訊: 英文 85 Pages
簡介

DNA疫苗,是以人類臨床部門作為對象的產品,數量上雖然比較少,但預計由於高銷售額該市場預計2016年終達到70億美元的規模。

本報告提供全球DNA疫苗市場相關調查分析,市場現況與展望,各市場區隔分析,主要推動因素與課題,最新趨勢,主要企業等系統性資訊。

第1章 分析師的見解

第2章 調查手法

第3章 DNA疫苗:簡介

第4章 推動因素與課題

  • 推動因素
  • 課題

第5章 DNA疫苗市場概要

第6章 各地區DNA疫苗市場

  • 北美
  • 歐洲
  • 亞太地區

第7章 各類型DNA疫苗市場

  • 重組蛋白疫苗
    • 各地區
  • 基因疫苗
    • 各地區

第8章 各終端用戶DNA疫苗市場

  • 動物

第9章 各治療指標DNA疫苗市場

  • 感染性及生物媒介性疾病
  • 癌症

第10章 開發平台分析

第11章 趨勢

第12章 企業簡介

  • Novartis International AG
  • Merck & Co., Inc
  • GlaxoSmithKline plc.
  • Sanofi
  • Zoetis
  • Green Cross Corporation
  • Inovio Pharmaceuticals, Inc.,
  • Bharat Biotech
  • Protein Sciences Corporation
  • Indian Immunologicals Ltd.
  • erum Institute of India Pvt. Ltd

建議

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The DNA vaccine in this report refers to the vaccines manufactured using recombinant DNA technology. The advent of these vaccines has revolutionized the healthcare market. These vaccines are more effective, as well as have less side-effects associated with them as compared to traditional vaccines. Various vaccines have been introduced in the market based on this technique. Some of the major DNA vaccines include GlaxoSmithKline's Engerix-B, Twinrix, and Fendrix; Merck's Gardasil, and Recombivax HB; Protein Sciences Corporation's Flublok, etc. Currently, the researchers are engaged in developing genetic vaccines for humans. Animal genetic vaccines are already present in the market. These vaccines are third generation vaccines, and contain DNA that codes for specific proteins from a pathogen. This DNA is injected into host body and produces protein for which the body generates immune response.

This comprehensive report by RNCOS entitled "Global DNA Vaccine Market Outlook 2022" provides an in-depth analysis of the global DNA Vaccines market, presenting readers a profound understanding of the various challenges, drivers, and developments in this industry. The study has publicized that though the numbers of DNA vaccines that target the human clinical segment are relatively fewer in number, however due to high sales of these vaccines, the DNA vaccine market is estimated to reach US$ 7 Billion by the end of 2016.

The report also contains detailed and in-depth analysis of the segmentation of the DNA vaccines market based on types of DNA vaccines, therapeutic indication, end-users, and geography. Based on the type, the DNA vaccines market is divided into recombinant protein and genetic. In 2016, recombinant protein segment is estimated to account for largest share in the market. This large share is attributed to the presence of high number of recombinant protein vaccines in the market.

Based on end-user, the report segments the market into human and animal. The majority of DNA vaccines available in the market are targeted for humans. Moreover, the strong pipeline of human targeted vaccines is likely to aid the market growth.

Based on geography, the report further divides the market into four regions, namely, North America, Europe, Asia-Pacific, and Rest of the World. North America is the largest market for DNA vaccines. The large share of the market is attributed to government's initiatives to immunize citizens, coupled with high awareness regarding the benefits of genetic vaccines targeted towards animals. The Asia-Pacific region is slated to witness the highest growth in the forecasted period. This growth is likely to be driven by rising awareness of people regarding the advantages of immunization against HPV and Hepatitis B.

The report also includes pipeline analysis based on the type of phase, therapeutic indications, and type of diseases for which the vaccines have been designed, such as infectious and vector borne diseases, and various types of cancers.

Major players in the DNA Vaccines market are also profiled with company overview, financial overview, product portfolios, recent developments, and strengths and weaknesses. The last section of the report discusses about the recommendations which could help the DNA vaccine market grow at a faster pace. Conclusively, the research will prove to be a useful resource for all debut makers in DNA vaccine industry, and potential investors.

Table of Contents

1. Analyst View

2. Research Methodology

3. DNA Vaccine - An Introduction

4. Drivers & Challenges

  • 4.1 Drivers
    • 4.1.1 Increasing Investment
    • 4.1.2 Advantages of DNA Vaccines over Traditional Vaccines
    • 4.1.3 Dramatic Increase in Chronic Disorders
    • 4.1.4 Strong DNA Vaccine Pipeline
    • 4.1.5 Technological Advancements
  • 4.2 Challenges
    • 4.2.1 Uncertainty in Regulatory System
    • 4.2.2 Lack of Awareness in Developing Countries
    • 4.2.3 Development Limited to Plasmid Vectors

5. DNA Vaccine Market Overview

6. DNA Vaccines Market by Geography

  • 6.1 North America
  • 6.2 Europe
  • 6.3 Asia Pacific

7. DNA Vaccine Market by Type

  • 7.1 Recombinant Protein Vaccines
    • 7.1.1 By Geography (North America, Europe, Asia Pacific)
  • 7.2 Genetic Vaccines
    • 7.2.1 By Geography (North America, Europe, Asia-Pacific)

8. DNA Vaccines Market by End User

  • 8.1 Human
  • 8.2 Animal

9. DNA Vaccines Market by Therapeutic Indication

  • 9.1 Infectious & Vector Borne Diseases
  • 9.2 Cancer

10. Pipeline Analysis

11. Trends

  • 11.1 Increasing Focus on Genetic Vaccine Development
  • 11.2 Expanding Applications Increasing Popularity of DNA Vaccines
  • 11.3 Partnerships Enhancing Genetic Vaccines Development

12. Company Profiles

  • 12.1 Novartis International AG
  • 12.2 Merck & Co., Inc
  • 12.3 GlaxoSmithKline plc.
  • 12.4 Sanofi
  • 12.5 Zoetis
  • 12.6 Green Cross Corporation
  • 12.7 Inovio Pharmaceuticals, Inc.,
  • 12.8 Bharat Biotech
  • 12.9 Protein Sciences Corporation
  • 12.10 Indian Immunologicals Ltd.
  • 12.11 Serum Institute of India Pvt. Ltd

13. Recommendations

List of Figures:

  • Figure 5-1: Share of DNA Vaccines in Global Vaccine Market (%), 2016
  • Figure 5-2: Share of DNA Vaccines in Global Vaccine Market (%), 2022
  • Figure 5-3: Global - DNA Vaccine Market (Billion US$), 2016-2022
  • Figure 6-1: Global - DNA Vaccine Market by Geography (%), 2016
  • Figure 6-2: Global - DNA Vaccine Market by Geography (%), 2022
  • Figure 6-3: North America - DNA Vaccine Market (Billion US$), 2016 & 2022
  • Figure 6-4: Europe - DNA Vaccine Market (Billion US$), 2016 & 2022
  • Figure 6-5: Asia Pacific - DNA Vaccine Market (Billion US$), 2016 & 2022
  • Figure 7-1: Global - DNA Vaccine Market by Type (%), 2016
  • Figure 7-2: Global - DNA Vaccine Market by Type (%), 2022
  • Figure 7-3: Global - Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-4: Global - Recombinant Protein Vaccines Market by Geography (%), 2016
  • Figure 7-5: Global - Recombinant Protein Vaccines Market by Geography (%), 2022
  • Figure 7-6: North America - Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-7: Europe - Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-8: Asia Pacific - Recombinant Protein Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-9: Global - Genetic Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-10: Global - Genetic Vaccines Market by Geography (%), 2016
  • Figure 7-11: Global - Genetic Vaccines Market by Geography (%), 2022
  • Figure 7-12: North America - Genetic Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-13: Europe - Genetic Vaccines Market (Billion US$), 2016 & 2022
  • Figure 7-14: Asia Pacific - Genetic Vaccines Market (Billion US$), 2016 & 2022
  • Figure 8-1: Global - DNA Vaccine Market by End User (%), 2016
  • Figure 8-2: Global - DNA Vaccine Market by End User (%), 2022
  • Figure 8-3: Global - Human DNA Vaccine Market (Billion US$), 2016 & 2022
  • Figure 8-4: Global - Animal DNA Vaccine Market (Billion US$), 2016 & 2022
  • Figure 9-1: Global - DNA Vaccine Market by Therapeutic Segment (%), 2016
  • Figure 9-2: Global - DNA Vaccine Market by Therapeutic Segment (%), 2022
  • Figure 9-3: Global - DNA Vaccine Market for Infectious & Vector Borne Diseases (Billion US$), 2016 & 2022
  • Figure 9-4: Global - DNA Vaccine Market for Cancer (Billion US$), 2016 & 2022
  • Figure 10-1: Global - DNA Vaccine Pipeline Analysis by Phase (%), 2016
  • Figure 10-2: Global - DNA Vaccine Pipeline by Therapeutic Indication (%), 2016
  • Figure 10-3: Global - DNA Vaccine Pipeline by Vaccine Type (%), 2016
  • Figure 10-4: Global - DNA Vaccine Pipeline by Application (%), 2016
  • Figure 12-1: Novartis - Break-up of Revenue by Product Category (%), 2015
  • Figure 12-2: Novartis - Break-up of Revenue by Geographical Region (%), 2015
  • Figure 12-3: Merck & Co. Inc - Break-up of Revenue by Product Category (%), 2015
  • Figure 12-4: Merck & Co. Inc - Break-up of Revenue by Geographical Region (%), 2015
  • Figure 12-5: GlaxoSmithKline - Break-up of Revenue by Product Category (%), 2015
  • Figure 12-6: GlaxoSmithKline - Break-up of Revenue by Geographical Region (%), 2015
  • Figure 12-7: Sanofi - Break-up of Revenue by Product Category (%), 2015
  • Figure 12-8: Sanofi - Break-up of Revenue by Geographical Region (%), 2015
  • Figure 12-9: Zoetis - Break-up of Revenue by Product Category (%), 2015
  • Figure 12-10: Zoetis - Break-up of Revenue by Geographical Region (%), 2015
  • Figure 12-11: Green Cross Corporation - Break-up of Revenue by Geographical Region (%), 2015

List of Tables:

  • Table 10-1: Global - DNA Vaccines Pipeline
  • Table 12-1: Novartis International AG - Product Portfolio
  • Table 12-2: Novartis International AG - Pipeline Analysis
  • Table 12-3: Novartis - Key Financials (Million US$), 2013-2015
  • Table 12-4: Merck & Co. Inc - Product Portfolio
  • Table 12-5: Merck & Co. Inc - Key Financials (Million US$), 2013-2015
  • Table 12-6: GlaxoSmithKline - Product Portfolio
  • Table 12-7: GlaxoSmithKline - Key Financials (Million US$), 2013-2015
  • Table 12-8: Sanofi - Product Portfolio
  • Table 12-9: Sanofi - Pipeline Analysis
  • Table 12-10: Sanofi - Key Financials (Million US$), 2013-2015
  • Table 12-11: Zoetis - Product Portfolio
  • Table 12-12: Zoetis - Key Financials (Million US$), 2013-2015
  • Table 12-13: Green Cross Corporation - Product Portfolio
  • Table 12-14: Green Cross Corporation - Key Financials (Million US$), 2013-2015
  • Table 12-15: Inovio Pharmaceuticals - Key Financials (Million US$), 2013-2015
  • Table 12-16: Inovio Pharmaceuticals - Pipeline Analysis
  • Table 12-17: Bharat Biotech - Product Portfolio
  • Table 12-18: Protein Sciences Corporation - Product Portfolio
  • Table 12-19: Protein Sciences Corporation - Pipeline Analysis
  • Table 12-20: Indian Immunologicals Ltd. - Product Portfolio
  • Table 12-21: Serum Institute of India Pvt. Ltd. - Product Portfolio
  • Table 12-22: Serum Institute of India Ltd. - Pipeline Analysis
Back to Top